厄洛替尼（特罗凯）用于治疗非小细胞肺癌和胰腺癌。
Erlotinib (tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer.
作者信息
Rocha-Lima Caio M, Raez Luis E
出版信息
P T. 2009 Oct;34(10):554-64.
Abstract
Erlotinib (Tarceva) is a small-molecule, orally dosed, anti-cancer drug that inhibits the epidermal growth factor receptor. Randomized, controlled clinical studies have demonstrated that erlotinib significantly improved survival in patients with previously treated non-small-cell lung cancer and, in combination with chemotherapy, in patients with untreated pancreatic cancer. In this article, we describe the clinical evidence and value of erlotinib as a therapy for non-small-cell lung cancer and pancreatic cancer and discuss ongoing clinical studies to optimize its use in various settings and to identify appropriate patient populations.
摘要
厄洛替尼（特罗凯）是一种口服的小分子抗癌药物，可抑制表皮生长因子受体。随机对照临床研究表明，厄洛替尼可显著提高既往接受过治疗的非小细胞肺癌患者的生存率，与化疗联合使用时，可提高未接受过治疗的胰腺癌患者的生存率。在本文中，我们描述了厄洛替尼作为非小细胞肺癌和胰腺癌治疗药物的临床证据和价值，并讨论了正在进行的临床研究，以优化其在各种情况下的使用，并确定合适的患者群体。
相似文献
1
Erlotinib (tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer.
P T. 2009 Oct;34(10):554-64.
2
Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Health Technol Assess. 2015 Jun;19(47):1-134. doi: 10.3310/hta19470.
3
Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Drugs R D. 2003;4(4):243-8. doi: 10.2165/00126839-200304040-00006.
4
Erlotinib (Tarceva): an update on the clinical trial program.
Semin Oncol. 2003 Jun;30(3 Suppl 7):34-46.
5
Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
J Clin Oncol. 2011 Nov 1;29(31):4113-20. doi: 10.1200/JCO.2010.31.8162. Epub 2011 Oct 3.
6
Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity.
Mol Cancer Ther. 2006 Aug;5(8):2051-9. doi: 10.1158/1535-7163.MCT-06-0007.
7
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Cochrane Database Syst Rev. 2016 May 25(5):CD010383. doi: 10.1002/14651858.CD010383.pub2.
8
Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer.
Future Oncol. 2007 Jun;3(3):247-54. doi: 10.2217/14796694.3.3.247.
9
Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
J Thorac Oncol. 2010 Oct;5(10):1616-22. doi: 10.1097/JTO.0b013e3181f1c7b0.
10
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
J Clin Oncol. 2005 Sep 1;23(25):5900-9. doi: 10.1200/JCO.2005.02.857. Epub 2005 Jul 25.
引用本文的文献
1
PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma.
Cancer Med. 2020 Oct;9(19):6972-6983. doi: 10.1002/cam4.3331. Epub 2020 Aug 10.
2
High frequency of exon 20 S768I EGFR mutation detected in malignant pleural effusions: A poor prognosticator of NSCLC.
Cancer Rep (Hoboken). 2020 Oct;3(5):e1262. doi: 10.1002/cnr2.1262. Epub 2020 Aug 6.
3
PTPRT epigenetic silencing defines lung cancer with STAT3 activation and can direct STAT3 targeted therapies.
Epigenetics. 2020 Jun-Jul;15(6-7):604-617. doi: 10.1080/15592294.2019.1676597. Epub 2019 Oct 13.
4
Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib.
Eur J Med Chem. 2019 Nov 15;182:111571. doi: 10.1016/j.ejmech.2019.111571. Epub 2019 Aug 9.
5
Oncolytic viral therapy for pancreatic cancer: current research and future directions.
Oncolytic Virother. 2014 Feb 17;3:35-46. doi: 10.2147/OV.S53858. eCollection 2014.
6
Pharmacokinetic properties of two erlotinib 150 mg formulations with a genetic effect evaluation in healthy Korean subjects.
Clin Drug Investig. 2015 Jan;35(1):31-43. doi: 10.1007/s40261-014-0248-4.
7
HMGA-targeted phosphorothioate DNA aptamers increase sensitivity to gemcitabine chemotherapy in human pancreatic cancer cell lines.
Cancer Lett. 2012 Feb 1;315(1):18-27. doi: 10.1016/j.canlet.2011.10.005. Epub 2011 Oct 10.
8
Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.
Curr Pharm Biotechnol. 2012 Jul;13(9):1817-33. doi: 10.2174/138920112800958850.
9
Oncolytic virotherapy for pancreatic cancer.
Expert Rev Mol Med. 2011 May 18;13:e18. doi: 10.1017/S1462399411001876.
本文引用的文献
1
The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis.
Br J Cancer. 2009 Feb 10;100(3):436-41. doi: 10.1038/sj.bjc.6604863.
2
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
N Engl J Med. 2008 Oct 23;359(17):1757-65. doi: 10.1056/NEJMoa0804385.
3
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.
J Clin Oncol. 2008 Sep 10;26(26):4268-75. doi: 10.1200/JCO.2007.14.8924. Epub 2008 Jul 14.
4
Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer.
Clin Ther. 2008 Apr;30(4):775-84. doi: 10.1016/j.clinthera.2008.04.016.
5
Second-line and third-line chemotherapy for lung cancer: use and cost.
Am J Manag Care. 2008 May;14(5):297-306.
6
Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer.
Cancer. 2008 Jun 15;112(12):2749-55. doi: 10.1002/cncr.23490.
7
New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.
Oncologist. 2008 Mar;13(3):289-98. doi: 10.1634/theoncologist.2007-0134.
8
Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC).
Lung Cancer. 2008 Sep;61(3):405-15. doi: 10.1016/j.lungcan.2007.12.023. Epub 2008 Mar 4.
9
Cancer statistics, 2008.
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.
10
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
J Clin Oncol. 2007 Oct 20;25(30):4787-92. doi: 10.1200/JCO.2007.11.8521.
Zotero 插件